H.C. Wainwright raised the firm’s price target on Cidara Therapeutics (CDTX) to $74 from $53 and keeps a Buy rating on the shares following the Q2 report. The company recently announced positive results from its Phase 2b trial, NAVIGATE, evaluating CD388 for the pre-exposure prophylaxis of seasonal influenza, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics price target raised to $66 from $59 at Citizens JMP
- Cidara Therapeutics Reports Positive Trial Results and Financial Growth
- Cidara Therapeutics reports Q2 EPS ($1.65), consensus ($1.82)
- Cidara Therapeutics price target raised to $115 from $75 at RBC Capital
- Cidara Therapeutics price target raised to $69 from $68 at Guggenheim